News
- Author:
- Neil Osterweil
Publish date: January 15, 2020
The bispecific anti-CD20/CD3 antibody induced complete responses in some heavily pretreated patients, incl...
News
- Author:
- Neil Osterweil
Publish date: January 9, 2020
ORLANDO – Genome and transcriptome sequencing identified both known mutational combinations and unexpected findings about myeloid disorders.
News
- Author:
- Neil Osterweil
Publish date: January 8, 2020
ORLANDO – The third-generation tyrosine kinase inhibitor ponatinib is active against Philadelphia chromosome–positive ALL with the T315I mutation.<...
News
- Author:
- Neil Osterweil
Publish date: January 2, 2020
Adding lomustine to temozolomide did not decrease quality of life for patients, apart from clinically insignificant differences in mental function....
News
- Author:
- Neil Osterweil
Publish date: December 30, 2019
A single application of intraoperative radiotherapy followed by standard chemotherapy and maintenance improved outcomes vs. those of historical con...
News
- Author:
- Neil Osterweil
Publish date: December 20, 2019
Exploratory analyses showed that patients with triple-negative breast cancer and PD-L1-positive tumors might benefit from durvalumab maintenance.
News
- Author:
- Neil Osterweil
Publish date: December 18, 2019
SAN ANTONIO – Palbociclib plus endocrine therapy was not superior to capecitabine in patients with HR-positive/HER2-n...
News
- Author:
- Neil Osterweil
Publish date: December 16, 2019
SAN ANTONIO – Liquid biopsy can identify patients with triple-negative breast cancer at high risk of relapse, but no ...
News
- Author:
- Neil Osterweil
Publish date: December 13, 2019
SAN ANTONIO – The immune checkpoint inhibitor added to standard chemotherapy increased the likelihood of a pathologic complete remission, regardles...
News
- Author:
- Neil Osterweil
Publish date: December 12, 2019
ORLANDO – A novel antibody targeted to the complement pathway increased hemoglobin and improved quality of life in patients with cold agglutinin di...
News
- Author:
- Neil Osterweil
Publish date: December 12, 2019
SAN ANTONIO – The overall response rate was 61% in heavily pretreated patients, but interstitial lung disease was a major side effect of the antibo...
News
- Author:
- Neil Osterweil
Publish date: December 12, 2019
SAN ANTONIO – The incidence of clinically relevant toxicity was similar between trastuzumab emtansine and trastuzumab...
News
- Author:
- Neil Osterweil
Publish date: December 9, 2019
ORLANDO – Despite modest efficacy, response durations, progression-free survival, and overall survival were short...
News
- Author:
- Neil Osterweil
Publish date: December 8, 2019
The use of a nurse navigation program to facilitate care helped iron out racial disparities that could lead to poor outcomes.
News
- Author:
- Neil Osterweil
Publish date: December 7, 2019
ORLANDO – A CAR T product targeting B-cell maturation antigen, one of several in development, was associated with a 100% overall response rate.
